Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck(German Center for Lung Research), Silvia Novello(University of Turin), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), С. В. Орлов(St Petersburg University), Maya Gottfried(Meir Medical Center), Anders Mellemgaard(AstraZeneca (United Kingdom)), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Claudia-Nanette Gann(Boehringer Ingelheim (Germany)), R. Kaiser(Boehringer Ingelheim (Germany)), Birgit Gaschler‐Markefski(Boehringer Ingelheim (Germany)), Meilin Liao(Shanghai Chest Hospital), José Barrueco(Georgetown University), Jean‐Yves Douillard(Integrated Oncology (United States)), Igor Bondarenko(Dnipro State Medical University)
The Lancet Oncology
January 8, 2014
10.1016/s1470-2045(13)70586-2
Cited by 948

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k